Nautilus Biotechnology, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2020 | — | $0 | $0 |
| FY2021 | — | $363.6M | $185.6M |
| FY2022 | — | $314.9M | $114.5M |
| FY2023 | — | $265.4M | $19.4M |
| FY2024 | — | $208.7M | $27.6M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2020 | — | $0 | $0 |
| FY2021 | — | $363.6M | $185.6M |
| FY2022 | — | $314.9M | $114.5M |
| FY2023 | — | $265.4M | $19.4M |
| FY2024 | — | $208.7M | $27.6M |